PRXL2B

Across TCGA pan-cancer cohorts, PRXL2B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRXL2B data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PRXL2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRXL2B expression acts as an unfavorable survival marker.

BLCA, GBM, and UCEC are the cancer types where PRXL2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.090	0.688	<.001	18	view →
GBM	OS	Median	All	0.089	0.413	.023	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	DFS	Median	All	0.249	0.728	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRXL2B–BLCA (OS)

Open the BLCA breakdown →